{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:21:11Z","timestamp":1791307271964,"version":"4.3.1"},"reference-count":23,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.2967\/jnumed.122.265346","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T15:40:47Z","timestamp":1686238847000},"page":"1252-1258","source":"Crossref","is-referenced-by-count":19,"title":["The Impact of PSMA PET\u2013Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen\u2013Targeted Radioligand Therapy"],"prefix":"10.2967","volume":"64","author":[{"given":"Amir","family":"Karimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Solaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Nekolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"D\u2019Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023080107250676000_64.8.1252.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2023080107250676000_64.8.1252.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023080107250676000_64.8.1252.3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2023080107250676000_64.8.1252.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023080107250676000_64.8.1252.5","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250676000_64.8.1252.6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2023080107250676000_64.8.1252.7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023080107250676000_64.8.1252.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"},{"key":"2023080107250676000_64.8.1252.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2023080107250676000_64.8.1252.10","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-014-0063-1"},{"key":"2023080107250676000_64.8.1252.11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals (Basel)."},{"key":"2023080107250676000_64.8.1252.12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00259-021-05473-2","article-title":"Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET\/CT using dual-tracer learning","volume":"49","author":"Capobianco","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250676000_64.8.1252.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023080107250676000_64.8.1252.14","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2022.40.16_suppl.5000","article-title":"TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel\u2014overall survival after median follow-up of 3 years (ANZUP 1603)","volume":"40","author":"Hofman","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023080107250676000_64.8.1252.15","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","article-title":"Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review","volume":"48","author":"Manafi-Farid","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250676000_64.8.1252.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264741"},{"key":"2023080107250676000_64.8.1252.17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2022.40.6_suppl.010","article-title":"PSMA PET and FDP PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)","volume":"40","author":"Buteau","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023080107250676000_64.8.1252.18","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implication of dual tracer PET\/CT: PSMA ligand and [18F] FDG PET\/CT in patients undergoing [177Lu] PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250676000_64.8.1252.19","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250676000_64.8.1252.20","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2023080107250676000_64.8.1252.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178228"},{"key":"2023080107250676000_64.8.1252.22","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023080107250676000_64.8.1252.23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T14:27:27Z","timestamp":1690900047000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.2967\/jnumed.122.265346"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265346","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}